The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ZOMD.F | +13.1% | -84.99% | -31.56% | -83% |
| S&P | +15% | +87.87% | +13.44% | +221% |
Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.
Investors bought back into the stock after it fell to its lowest point in two months.
Don't jump on these bandwagons unless you're willing to lose most of your money.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $8.10M | 15.7% |
| Gross Profit | $5.44M | 79.3% |
| Gross Margin | 67.15% | 23.8% |
| Market Cap | $77.32M | -42.5% |
| Market Cap / Employee | $508.67K | 0.0% |
| Employees | 152 | 0.0% |
| Net Income | -$6,121.00K | 8.6% |
| EBITDA | -$4,706.00K | 13.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.50M | -23.1% |
| Accounts Receivable | $3.14M | 78.7% |
| Inventory | 5.5 | 1.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.65M | 14.0% |
| Short Term Debt | $705.00K | 11.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -49.00% | -23.6% |
| Return On Invested Capital | -15.52% | 184.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4,736.56K | 20.2% |
| Operating Free Cash Flow | -$4,694.17K | 3.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.58 | 0.29 | 0.30 | 0.62 | -4.25% |
| Price to Sales | 4.31 | 2.07 | 1.40 | 2.63 | -47.82% |
| Price to Tangible Book Value | 1.11 | 0.58 | 0.44 | 0.92 | -24.70% |
| Enterprise Value to EBITDA | -7.86 | 0.63 | 2.60 | -5.64 | -48.82% |
| Return on Equity | -21.6% | -55.8% | -50.9% | -52.4% | 95.39% |
| Total Debt | $1.81M | $2.68M | $2.52M | $2.35M | 13.29% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
